{"entity":{"type":"insider","cik":"0001769012","url":"/insider/0001769012","json_url":"/insider/0001769012.json","name":"ARCH Venture Partners X, LLC","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":16,"n_filings":10,"first":"2019-02-26","last":"2026-07-06","span_basis":"filed_date"},"name_variants":[{"name":"ARCH Venture Partners X, LLC","source":"filing","n_filings":10,"first_seen":"2019-02-26","last_seen":"2026-07-06"}],"transactions":[{"id":5892202,"accession":"0001012975-26-000621","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001012975-26-000621","line_url":"/filing/0001012975-26-000621#line-2","is_derivative":false,"issuer_cik":"0001666306","issuer_name":"Boundless Bio, Inc.","issuer_ticker":"BOLD","issuer_name_source":null,"issuer_url":"/issuer/0001666306","owner_cik":null,"owner_name":"ARCH Venture Fund X Overage, L.P.; ARCH Venture Partners IX, L.P.; ARCH Venture Fund IX Overage, L.P.; ARCH Venture Fund IX, L.P.; ARCH Venture Partners IX Overage, L.P.; ARCH Venture Partners X, LLC; ARCH Venture Partners IX, LLC; ARCH Venture Partners X Overage, L.P.","owner_display_name":"ARCH Venture Fund X Overage, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":16000.0,"shares_display":"16,000","price_per_share":2.49,"price_display":"2.49","price_state":"stated","total_value":39840.0,"total_display":"39,840.00","total_whole":"39,840","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-07-01","filed_date":"2026-07-06","scope":"insider"},{"id":5119195,"accession":"0001012975-25-000679","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001012975-25-000679","line_url":"/filing/0001012975-25-000679#line-1","is_derivative":false,"issuer_cik":"0001402439","issuer_name":"Neumora Therapeutics, Inc.","issuer_ticker":"NMRA","issuer_name_source":null,"issuer_url":"/issuer/0001402439","owner_cik":null,"owner_name":"ARCH Venture Fund X, L.P.; ARCH Venture Fund VII, L.P.; ARCH Venture Partners X, L.P.; ARCH Venture Partners X Overage, L.P.; ARCH Venture Partners X, LLC; ARCH Venture Partners VII, L.P.; ARCH Venture Fund VIII Overage, L.P.; ARCH Venture Fund X Overage, L.P.; ARCH Venture Partners VII, LLC; ARCH Venture Partners VIII, LLC","owner_display_name":"ARCH Venture Fund X, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1915700.0,"shares_display":"1,915,700","price_per_share":2.61,"price_display":"2.61","price_state":"stated","total_value":4999977.0,"total_display":"4,999,977.00","total_whole":"4,999,977","shares_owned_after":6046907.0,"shares_owned_after_display":"6,046,907","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-10-27","filed_date":"2025-10-29","scope":"insider"},{"id":4874763,"accession":"0001062993-25-013460","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001062993-25-013460","line_url":"/filing/0001062993-25-013460#line-1","is_derivative":false,"issuer_cik":"0001219039","issuer_name":"Prime Medicine, Inc.","issuer_ticker":"PRME","issuer_name_source":null,"issuer_url":"/issuer/0001219039","owner_cik":null,"owner_name":"ARCH Venture Partners X, L.P.; ARCH Venture Partners X Overage, L.P.; GILLIS STEVEN; ARCH Venture Partners X, LLC; ARCH Venture Fund X, L.P.; ARCH Venture Fund X Overage, L.P.; Burow Kristina; CRANDELL KEITH","owner_display_name":"ARCH Venture Partners X, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":3030300.0,"shares_display":"3,030,300","price_per_share":3.3,"price_display":"3.30","price_state":"stated","total_value":9999990.0,"total_display":"9,999,990.00","total_whole":"9,999,990","shares_owned_after":6230300.0,"shares_owned_after_display":"6,230,300","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-08-01","filed_date":"2025-08-01","scope":"insider"},{"id":3151686,"accession":"0000950170-24-041841","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0000950170-24-041841","line_url":"/filing/0000950170-24-041841","is_derivative":false,"issuer_cik":"0001666306","issuer_name":"Boundless Bio, Inc.","issuer_ticker":"BOLD","issuer_name_source":null,"issuer_url":"/issuer/0001666306","owner_cik":null,"owner_name":"ARCH Venture Fund IX Overage, L.P.; ARCH Venture Fund IX, L.P.; ARCH Venture Fund X Overage, L.P.; ARCH Venture Partners IX Overage, L.P.; ARCH Venture Partners IX, L.P.; ARCH Venture Partners IX, LLC; ARCH Venture Partners X Overage, L.P.; ARCH Venture Partners X, LLC","owner_display_name":"ARCH Venture Fund IX Overage, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":200000.0,"shares_display":"200,000","price_per_share":16.0,"price_display":"16.00","price_state":"stated","total_value":3200000.0,"total_display":"3,200,000.00","total_whole":"3,200,000","shares_owned_after":1181766.0,"shares_owned_after_display":"1,181,766","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-04-02","filed_date":"2024-04-04","scope":"insider","n_lines":2},{"id":2431765,"accession":"0001062993-24-003738","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001062993-24-003738","line_url":"/filing/0001062993-24-003738#line-1","is_derivative":false,"issuer_cik":"0001219039","issuer_name":"Prime Medicine, Inc.","issuer_ticker":"PRME","issuer_name_source":null,"issuer_url":"/issuer/0001219039","owner_cik":null,"owner_name":"ARCH Venture Partners X Overage, L.P.; ARCH Venture Partners X, LLC; ARCH Venture Fund X, L.P.; Burow Kristina; GILLIS STEVEN; ARCH Venture Fund X Overage, L.P.; ARCH Venture Partners X, L.P.; CRANDELL KEITH","owner_display_name":"ARCH Venture Partners X Overage, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":3200000.0,"shares_display":"3,200,000","price_per_share":6.25,"price_display":"6.25","price_state":"stated","total_value":20000000.0,"total_display":"20,000,000.00","total_whole":"20,000,000","shares_owned_after":3200000.0,"shares_owned_after_display":"3,200,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-02-15","filed_date":"2024-02-20","scope":"insider"},{"id":2997071,"accession":"0001062993-24-002840","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001062993-24-002840","line_url":"/filing/0001062993-24-002840","is_derivative":false,"issuer_cik":"0001666306","issuer_name":"Sana Biotechnology, Inc.","issuer_ticker":"SANA","issuer_name_source":null,"issuer_url":"/issuer/0001666306","owner_cik":null,"owner_name":"ARCH Venture Fund X Overage, L.P.; ARCH Venture Fund X, L.P.; ARCH Venture Partners IX Overage, L.P.; ARCH Venture Partners IX, L.P.; ARCH Venture Partners IX, LLC; ARCH Venture Partners X, L.P.; ARCH Venture Fund IX, L.P.; ARCH Venture Partners X Overage, L.P.; ARCH Venture Fund IX Overage, L.P.; ARCH Venture Partners X, LLC","owner_display_name":"ARCH Venture Fund X Overage, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1818181.0,"shares_display":"1,818,181","price_per_share":5.5,"price_display":"5.50","price_state":"stated","total_value":9999995.5,"total_display":"9,999,995.50","total_whole":"9,999,996","shares_owned_after":12446022.0,"shares_owned_after_display":"12,446,022","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-02-08","filed_date":"2024-02-12","scope":"insider","n_lines":3},{"id":8280406,"accession":"0000899243-23-019274","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0000899243-23-019274","line_url":"/filing/0000899243-23-019274#line-6","is_derivative":false,"issuer_cik":"0001219039","issuer_name":"Neumora Therapeutics, Inc.","issuer_ticker":"NMRA","issuer_name_source":null,"issuer_url":"/issuer/0001219039","owner_cik":null,"owner_name":"BYBEE CLINTON; ARCH Venture Partners X, LLC; GILLIS STEVEN; ARCH Venture Fund XII, L.P.; NELSEN ROBERT; ARCH Venture Partners XII, L.P.; ARCH Venture Partners XII, LLC; CRANDELL KEITH","owner_display_name":"BYBEE CLINTON","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1500000.0,"shares_display":"1,500,000","price_per_share":17.0,"price_display":"17.00","price_state":"stated","total_value":25500000.0,"total_display":"25,500,000.00","total_whole":"25,500,000","shares_owned_after":3624143.0,"shares_owned_after_display":"3,624,143","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-09-19","filed_date":"2023-09-20","scope":"insider"},{"id":7915440,"accession":"0000899243-23-019273","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0000899243-23-019273","line_url":"/filing/0000899243-23-019273#line-6","is_derivative":false,"issuer_cik":"0001402439","issuer_name":"Neumora Therapeutics, Inc.","issuer_ticker":"NMRA","issuer_name_source":null,"issuer_url":"/issuer/0001402439","owner_cik":null,"owner_name":"ARCH Venture Fund VII, L.P.; ARCH Venture Fund X, L.P.; ARCH Venture Partners VII, LLC; ARCH Venture Partners X, L.P.; ARCH Venture Partners X, LLC; ARCH Venture Partners X Overage, L.P.; ARCH Venture Partners VII, L.P.; ARCH Venture Partners VIII, LLC; ARCH Venture Fund VIII Overage, L.P.; ARCH Venture Fund X Overage, L.P.","owner_display_name":"ARCH Venture Fund VII, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1500000.0,"shares_display":"1,500,000","price_per_share":17.0,"price_display":"17.00","price_state":"stated","total_value":25500000.0,"total_display":"25,500,000.00","total_whole":"25,500,000","shares_owned_after":3624143.0,"shares_owned_after_display":"3,624,143","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-09-19","filed_date":"2023-09-20","scope":"insider"},{"id":6870829,"accession":"0001628280-22-027125","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001628280-22-027125","line_url":"/filing/0001628280-22-027125","is_derivative":false,"issuer_cik":"0001219039","issuer_name":"Prime Medicine, Inc.","issuer_ticker":"PRME","issuer_name_source":null,"issuer_url":"/issuer/0001219039","owner_cik":null,"owner_name":"ARCH Venture Partners X, LLC; GILLIS STEVEN; CRANDELL KEITH; ARCH Venture Partners X, L.P.; ARCH Venture Fund X, L.P.; ARCH Venture Partners X Overage, L.P.; ARCH Venture Fund X Overage, L.P.; Burow Kristina","owner_display_name":"ARCH Venture Partners X, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":800000.0,"shares_display":"800,000","price_per_share":17.0,"price_display":"17.00","price_state":"stated","total_value":13600000.0,"total_display":"13,600,000.00","total_whole":"13,600,000","shares_owned_after":6128297.0,"shares_owned_after_display":"6,128,297","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-10-24","filed_date":"2022-10-26","scope":"insider","n_lines":2},{"id":8309475,"accession":"0001012975-19-000199","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001012975-19-000199","line_url":"/filing/0001012975-19-000199","is_derivative":false,"issuer_cik":"0001219039","issuer_name":"Sienna Biopharmaceuticals, Inc.","issuer_ticker":"SNNA","issuer_name_source":null,"issuer_url":"/issuer/0001219039","owner_cik":null,"owner_name":"ARCH Venture Partners X, LLC; ARCH Venture Partners X Overage, L.P.; CRANDELL KEITH; NELSEN ROBERT; ARCH Venture Fund X Overage, L.P.; GILLIS STEVEN","owner_display_name":"ARCH Venture Partners X, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2165800.0,"shares_display":"2,165,800","price_per_share":2.5,"price_display":"2.50","price_state":"stated","total_value":5414500.0,"total_display":"5,414,500.00","total_whole":"5,414,500","shares_owned_after":1865800.0,"shares_owned_after_display":"1,865,800","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-02-22","filed_date":"2019-02-26","scope":"insider","n_lines":3}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001782303","name":"Boundless Bio, Inc.","url":"/issuer/0001782303","role":"Ten percent owner","n_filings":2,"first_seen":"2024-04-04","last_seen":"2026-07-06"},{"type":"issuer","type_label":"ISSUER","cik":"0001885522","name":"Neumora Therapeutics, Inc.","url":"/issuer/0001885522","role":"Ten percent owner","n_filings":3,"first_seen":"2023-09-20","last_seen":"2025-10-29"},{"type":"issuer","type_label":"ISSUER","cik":"0001894562","name":"Prime Medicine, Inc.","url":"/issuer/0001894562","role":"Ten percent owner","n_filings":3,"first_seen":"2022-10-26","last_seen":"2025-08-01"},{"type":"issuer","type_label":"ISSUER","cik":"0001770121","name":"Sana Biotechnology, Inc.","url":"/issuer/0001770121","role":"Ten percent owner","n_filings":1,"first_seen":"2024-02-12","last_seen":"2024-02-12"},{"type":"issuer","type_label":"ISSUER","cik":"0001656328","name":"Sienna Biopharmaceuticals, Inc.","url":"/issuer/0001656328","role":"Ten percent owner","n_filings":1,"first_seen":"2019-02-26","last_seen":"2019-02-26"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001769012","retrieved_at":"2026-08-22T20:36:50+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}